Neurocrine Biosciences, Inc. NBIX
171.62 USD -2.79 (-1.60%)
Nov 12, 2026, 1:59 PM EST
169.88 Day range 173.98
122.14 52-week range 186.12
- YTD
- +21.00%
- 1 year
- +16.87%
News
zacks.com NBIX or GRDN: Which Is the Better Value Stock Right Now? Investors interested in stocks from the Medical - Drugs sector have probably already heard of Neurocrine Biosciences (NBIX) and Guardian Pharmacy Services (GRDN). But which of these two stocks…
prnewswire.com Neurocrine Biosciences to Present at the 2026 Jefferies Global Healthcare Conference SAN DIEGO, Nov. 10, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that its executives will participate at the 2026 Jefferies Global Healthcare Conference in London…
zacks.com Looking for a Growth Stock? 3 Reasons Why Neurocrine (NBIX) is a Solid Choice Neurocrine (NBIX) could produce exceptional returns because of its solid growth attributes.
zacks.com All You Need to Know About Neurocrine (NBIX) Rating Upgrade to Buy Neurocrine (NBIX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
zacks.com NBIX vs. GRDN: Which Stock Is the Better Value Option? Investors looking for stocks in the Medical - Drugs sector might want to consider either Neurocrine Biosciences (NBIX) or Guardian Pharmacy Services (GRDN). But which of these two companies is the…
zacks.com Wall Street Analysts See a 25.53% Upside in Neurocrine (NBIX): Can the Stock Really Move This High? The average of price targets set by Wall Street analysts indicates a potential upside of 25.5% in Neurocrine (NBIX). While the effectiveness of this highly sought-after metric is questionable, the…
benzinga.com Neurocrine Biosciences Releases Findings From New Survey Showing Adults With Tardive Dyskinesia Reported Fewer Disruptions To Work, School After Starting Treatment With INGREZZA Capsules Survey reveals work or school disruptions among adults with tardive dyskinesia declined from 57% before treatment to 21% after starting INGREZZA, with average missed days per month decreasing from…
prnewswire.com Neurocrine Biosciences Presents New Tardive Dyskinesia Survey Results Showing Fewer Work and School Disruptions with INGREZZA® (valbenazine) Capsules Survey reveals work or school disruptions among adults with tardive dyskinesia declined from 57% before treatment to 21% after starting INGREZZA, with average missed days per month decreasing from…
defenseworld.net Neurocrine Biosciences, Inc. $NBIX Shares Newly Bought by Factory Mutual Insurance Co. Factory Mutual Insurance Co. acquired a new stake in shares of Neurocrine Biosciences, Inc. (NASDAQ: NBIX) during the undefined quarter, according to the company in its most recent 13F filing with…
seekingalpha.com Neurocrine Biosciences: Breaking Down A Solid Quarter Neurocrine Biosciences delivered robust Q3 results Monday after the bell, with EPS of $3.29 and revenue up 41% to $1.12 billion. INGREZZA remains NBIX's primary growth driver, posting 17%…
benzinga.com Guggenheim Maintains Buy on Neurocrine Biosciences, Raises Price Target to $224 Guggenheim analyst Delma Caiati maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises the price target from $207 to $224.
benzinga.com Morgan Stanley Maintains Equal-Weight on Neurocrine Biosciences, Raises Price Target to $185 Morgan Stanley analyst Jeffrey Hung maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Equal-Weight and raises the price target from $183 to $185.
benzinga.com Nasdaq 100 Gets a Lift As Nvidia Overtakes Apple: Stock Market Today Apple's memory-cost margin warning hands Nvidia the top market value as chipmakers rebound. Here's what's happening in the stock market today.
benzinga.com Fabrinet, EverQuote, Lattice Semiconductor, Fiserv And Other Big Stocks Moving Higher On Tuesday U.S. stocks mixed as Dow fell 200 points; Fabrinet surged 13.7% on strong results, guidance and buyback, while several small caps rallied.- benzinga.com RBC Capital Maintains Outperform on Neurocrine Biosciences, Raises Price Target to $190 RBC Capital analyst Brian Abrahams maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Outperform and raises the price target from $187 to $190.
- benzinga.com Canaccord Genuity Maintains Buy on Neurocrine Biosciences, Raises Price Target to $220 Canaccord Genuity analyst Sumant Kulkarni maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises the price target from $210 to $220.
benzinga.com Piper Sandler Maintains Overweight on Neurocrine Biosciences, Raises Price Target to $215 Piper Sandler analyst David Amsellem maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Overweight and raises the price target from $210 to $215.
benzinga.com Neurocrine Biosciences Raises FY 2026 INGREZZA Net Product Sales Guidance from $2.825B-$2.875B to $2.900B-$2.925B Neurocrine Biosciences (NASDAQ:NBIX) Raises FY 2026 INGREZZA Net Product Sales Guidance from $2.825B-$2.875B to $2.900B-$2.925B
benzinga.com Neurocrine Biosciences Q3 Adj. EPS $3.29 Beats $1.91 Estimate, Sales $1.119B Beat $1.043B Estimate Neurocrine Biosciences (NASDAQ:NBIX) reported quarterly earnings of $3.29 per share which beat the analyst consensus estimate of $1.91 by 72.25 percent. This is a 51.61 percent increase over earnings…
benzinga.com Apple, Palantir On Deck Monday As AI Demand, iPhone Growth Face Test Apple headlines Monday’s reports, with investors looking for continued iPhone momentum and evidence that its artificial-intelligence push can support the company’s next leg of growth. Marriott…- benzinga.com Neurocrine Biosciences Identifies Clinically Meaningful Health Improvement Threshold For INGREZZA In Tardive Dyskinesia Patients New analysis establishes a 6-point increase on the EQ Visual Analogue Scale as a threshold for clinically meaningful change in overall health ratings in patients with tardive dyskinesia treated with
- benzinga.com Neurocrine Biosciences Announces Publication Of Expert Perspectives Highlighting Hyperphagia In Prader-Willi Syndrome As Neurobiologically Driven Condition Expert perspectives highlight the interaction of hypothalamic dysfunction, biological, behavioral, and environmental factors in shaping the challenges of hyperphagia in Prader-Willi syndrome for…
benzinga.com Neurocrine Biosciences Starts Phase 2 Clinical Trial Of NBI-1117567 To Treat Adults With Mild To Moderate Alzheimer's Disease Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced the initiation of its Phase 2 clinical study of investigational compound NBI-1117567 (NBI-'567) in adults with mild to moderate Alzheimer's…
benzinga.com Neurocrine Biosciences To Report Impact Of Classical Congenital Adrenal Hyperplasia At Endocrine Nurses Society Annual Symposium 2026 Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new real-world data demonstrating how the clinical and day-to-day impact of classic congenital adrenal hyperplasia can vary among…- benzinga.com Needham Reiterates Buy on Neurocrine Biosciences, Maintains $204 Price Target Needham analyst Ami Fadia reiterates Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and maintains $204 price target.
- benzinga.com BMO Capital Maintains Market Perform on Neurocrine Biosciences, Lowers Price Target to $150 BMO Capital analyst Evan Seigerman maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Market Perform and lowers the price target from $164 to $150.
- benzinga.com Guggenheim Assumes Neurocrine Biosciences at Buy, Announces Price Target of $207 Guggenheim analyst Delma Caiati assumes Neurocrine Biosciences (NASDAQ:NBIX) with a Buy rating and announces Price Target of $207.
- benzinga.com UBS Maintains Buy on Neurocrine Biosciences, Lowers Price Target to $214 UBS analyst Ashwani Verma maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and lowers the price target from $231 to $214.
- benzinga.com Morgan Stanley Maintains Equal-Weight on Neurocrine Biosciences, Raises Price Target to $183 Morgan Stanley analyst Jeffrey Hung maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Equal-Weight and raises the price target from $182 to $183.
- benzinga.com RBC Capital Reiterates Outperform on Neurocrine Biosciences, Maintains $198 Price Target RBC Capital analyst Brian Abrahams reiterates Neurocrine Biosciences (NASDAQ:NBIX) with a Outperform and maintains $198 price target.
benzinga.com Citigroup Maintains Buy on Neurocrine Biosciences, Raises Price Target to $253 Citigroup analyst Yigal Nochomovitz maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises the price target from $249 to $253.- benzinga.com Neurocrine Receives FDA Investigational New Drug Acceptance For NBI-1117567 Phase 2 Alzheimer's Study, Triggering $10M Payment To Nxera NBI-1117567 is an investigational oral, muscarinic M1 preferring (M1/M4) selective agonist discovered by Nxera and advancing through clinical development under a multi-program collaboration with…
benzinga.com 10 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com 10 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com Jim Cramer Says Buy Uber, Calls Rockwell Automation 'One Ugly Chart' but a 'Great Long-Term Situation' Jim Cramer recommended buying Uber, Tanger, Rockwell Automation, Amcor, and Neurocrine Biosciences. Uber and Zipline announced a partnership for autonomous delivery. Tanger and Amcor both reported…- benzinga.com Morgan Stanley Maintains Equal-Weight on Neurocrine Biosciences, Lowers Price Target to $182 Morgan Stanley analyst Jeffrey Hung maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Equal-Weight and lowers the price target from $196 to $182.
benzinga.com What's Going On With Neurocrine Biosciences Stock On Wednesday? Reports of serious adverse events and deaths linked to Neurocrine's VYKAT XR for Prader-Willi syndrome prompt caution.- benzinga.com Neurocrine Biosciences Announces Publication Of Its KINCET-PRO Phase 4 Study Results Showing That Once-Daily INGREZZA Capsules Led To Substantial And Sustained Improvements In Patient-Reported Quality Of Life And Functionality INGREZZA is the only vesicular monoamine transporter 2 inhibitor with clinical trial data demonstrating improvements in quality of life and functionality in people living with tardive dyskinesia…
- benzinga.com Neurocrine Biosciences Initiates Phase 1 First-In-Human Clinical Study Evaluating NBIP-'1968, Investigational GLP-1/GIP/Glucagon Receptor Triple Agonist Being Developed As Therapy For Obesity Initiation of study marks an important milestone in advancing Neurocrine's obesity portfolio and investigational metabolic disease pipeline SAN DIEGO, Aug. 7, 2026 /PRNewswire/ -- Neurocrine…
- benzinga.com Canaccord Genuity Maintains Buy on Neurocrine Biosciences, Raises Price Target to $210 Canaccord Genuity analyst Sumant Kulkarni maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises the price target from $200 to $210.
- benzinga.com Truist Securities Maintains Buy on Neurocrine Biosciences, Raises Price Target to $213 Truist Securities analyst Danielle Brill maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises the price target from $200 to $213.
- benzinga.com Wedbush Maintains Outperform on Neurocrine Biosciences, Raises Price Target to $194 Wedbush analyst Laura Chico maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Outperform and raises the price target from $185 to $194.
- benzinga.com Citigroup Maintains Buy on Neurocrine Biosciences, Raises Price Target to $249 Citigroup analyst Yigal Nochomovitz maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises the price target from $246 to $249.
benzinga.com RBC Capital Maintains Outperform on Neurocrine Biosciences, Raises Price Target to $198 RBC Capital analyst Brian Abrahams maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Outperform and raises the price target from $195 to $198.- benzinga.com Morgan Stanley Maintains Equal-Weight on Neurocrine Biosciences, Raises Price Target to $196 Morgan Stanley analyst Jeffrey Hung maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Equal-Weight and raises the price target from $193 to $196.
- benzinga.com TD Cowen Maintains Buy on Neurocrine Biosciences, Raises Price Target to $220 TD Cowen analyst Phil Nadeau maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises the price target from $200 to $220.
- benzinga.com Piper Sandler Maintains Overweight on Neurocrine Biosciences, Raises Price Target to $210 Piper Sandler analyst David Amsellem maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Overweight and raises the price target from $207 to $210.
- benzinga.com Cantor Fitzgerald Maintains Overweight on Neurocrine Biosciences, Raises Price Target to $215 Cantor Fitzgerald analyst Josh Schimmer maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Overweight and raises the price target from $210 to $215.
- benzinga.com Guggenheim Maintains Buy on Neurocrine Biosciences, Raises Price Target to $222 Guggenheim analyst Yatin Suneja maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises the price target from $200 to $222.
- benzinga.com Stifel Maintains Buy on Neurocrine Biosciences, Raises Price Target to $215 Stifel analyst Paul Matteis maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises the price target from $188 to $215.